TickerTalks
Browse all tickers →
TickerTalks›$PCRX
PCPCRX

Pacira BioSciences, Inc.

$PCRX·$1.4B·Drug Manufacturers - Specialty & Generic·Healthcare
$36.34+0.0%1Y+59.6%
Price updated 8h ago·X counts updated 5d ago
PCPCRX
$PCRXPacira BioSciences, Inc.
$36.34+0.03%321 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PCRX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

321X posts · last 7 days
Oct 4Oct 11
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $PCRX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 82% of tracked names.

What it does

Plain-English summary of the business — what they sell and how they make money.

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $PCRX.

Drug Manufacturers - Specialty & Generic · Healthcare

Specialty pharma is bifurcating — GLP-1 adjacent programs attract premium valuations while generic manufacturers face pricing erosion from FDA approval backlogs clearing. Biosimilar launches of adalimumab (Humira), ustekinumab, and etanercept are accelerating branded erosion timelines, while mid-tier specialty pharma focuses on complex generics (ophthalmic, inhalation) to sustain margins.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
103.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
1.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
2.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
12.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
2.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$0.73$0.65+13.0%
Q1 2026Apr 30, 2026$0.60$0.61-1.6%
Q4 2025Feb 26, 2026$0.57$0.85-32.9%
Q3 2025Nov 6, 2025$0.70$0.65+7.7%
Next earningsThu, Nov 5·consensus EPS $0.73

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$192.4M+6.2%77.0%2.2%$0.12$56.1M
Q1 FY26$177.4M+5.0%79.5%2.6%$0.07$23.0M
Q4 FY25$196.9M+5.1%79.5%1.6%$0.04$43.5M
Q3 FY25$179.5M+6.5%80.9%3.5%$0.12$57.0M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$754.4M$751.3M – $757.4M$2.90$2.84 – $2.976
FY27$789.7M$784.8M – $794.0M$3.46$3.17 – $3.676
FY28$883.5M$799.0M – $1.2B$4.61$4.43 – $4.987
FY29$866.4M$841.1M – $920.2M$4.53$4.36 – $4.893
FY30$836.4M$812.0M – $888.4M$4.22$4.06 – $4.565

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.98%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+36.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+49.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 38.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.255-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 8Lauren RikerPresident6.0K sh$218KSellAug 17Jonathan SloninChief Medical Officer3.0K sh$71KSellJun 11Lauren RikerPresident6.1K sh$144KSellJun 4Kristen WilliamsChief Administrative Officer10.3K sh$228KSellApr 23Shawn CrossCFO12.9K sh$326KSellApr 22Shawn CrossCFO1.5K sh$38KSellApr 20Shawn CrossCFO7.7K sh$194K
+ 16 other (8 awards · 5 exempts · 3 inkinds) in window

See when $PCRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentOct 13SC 13D/A
8-KMaterial agreementOct 88-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
8-KMaterial agreementJun 308-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
3New insider — initial holdingsJun 123
8-KOfficer or director changeJun 118-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote · Item 8.01: Other event
+ 32 other (13 proxys · 5 DFAN14As · 3 13Gs · 2 SC TO-Cs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?gurufocus.com·4d agoAre OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?prnewswire.com·4d agoPacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRXbusinesswire.com·5d agoSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)gurufocus.com·6d agoSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)prnewswire.com·6d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEVA$ACB$ZTS$ZYBT$ELAN$EVO$INDV$EBS
Voices on X · last 7 days

No standout posts about $PCRX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport